ReShape Lifesciences Stock Price, News & Analysis

ReShape Lifesciences Inc. (formerly trading on Nasdaq under the symbol RSLS) has historically operated in the surgical and medical instrument manufacturing space, with a focus on weight loss and metabolic health solutions. According to company disclosures, ReShape Lifesciences described itself as a physician-led weight loss and metabolic health-solutions company, offering products and technologies intended to manage and treat obesity and related metabolic diseases.

Public filings and news releases indicate that ReShape Lifesciences’ business centered on obesity treatment devices and related technologies. The company highlighted the Lap-Band® System, an FDA-approved, minimally invasive, long-term treatment for obesity that is positioned as an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. ReShape Lifesciences also described the Lap-Band® 2.0 FLEX system, which it characterized as an enhanced, next-generation version of the Lap-Band® platform. In addition, the company referenced its Obalon® balloon technology, a non-surgical, swallowable, gas-filled intragastric balloon designed to provide long-lasting weight loss.

Beyond gastric banding and balloon technologies, ReShape Lifesciences reported development work on neuromodulation approaches for metabolic disease. In its communications, the company described an investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system, utilizing a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. In some disclosures, this platform was also referred to more generally as an investigational vagal neuromodulation system for type 2 diabetes and metabolic conditions.

ReShape Lifesciences also emphasized its intellectual property position. In a July 2025 announcement, the company stated that the U.S. Patent and Trademark Office would issue a patent entitled “Intragastric Device,” covering an intragastric balloon system comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open around three months after inflation with saline liquid, configured for natural excretion after deflation. The company indicated that this patent is part of a broader portfolio of patents related to intragastric balloon technology and other proprietary technologies.

Corporate developments disclosed in SEC filings and news releases show that ReShape Lifesciences entered into a significant strategic transaction. Under an Agreement and Plan of Merger dated July 8, 2024, as amended, ReShape Lifesciences (through a wholly owned subsidiary, Raider Lifesciences Inc.) agreed to merge with Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases. On August 15, 2025, the merger closed, with Raider Lifesciences merging into Vyome, and Vyome surviving as a subsidiary of the public company. As a result of the merger, the public entity formerly known as ReShape Lifesciences Inc. was renamed Vyome Holdings, Inc., effective before the open of trading on August 15, 2025.

Concurrent with the merger, ReShape Lifesciences also completed an asset sale. Under an Asset Purchase Agreement with Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd. (together, Biorad), ReShape Lifesciences sold substantially all of its assets (excluding cash) to Biorad, and Biorad assumed substantially all of ReShape’s liabilities, for an agreed purchase price in cash subject to adjustment based on specified account balances. Company disclosures state that the assets sold included ReShape’s Lap-Band® System, Obalon® Gastric Balloon System, and the DBSN™ system.

Following these transactions, the former RSLS-listed company no longer operates under the ReShape Lifesciences name. Trading of the company’s common stock on The Nasdaq Capital Market continued on a split-adjusted basis under the new name Vyome Holdings, Inc. and the trading symbol HIND, beginning with the open of trading on August 15, 2025. SEC filings describe a 1-for-4 reverse stock split of the company’s common stock that was effected on August 15, 2025, primarily intended to help the company meet Nasdaq’s minimum bid price requirements in connection with the merger.

Because of these corporate changes, the RSLS ticker represents the historical listing for ReShape Lifesciences Inc. prior to its transformation into Vyome Holdings, Inc. Investors researching RSLS are typically examining the legacy weight loss and metabolic health device business, the terms of the merger with Vyome Therapeutics, and the asset sale to Biorad Medisys, as documented in the company’s SEC filings and public announcements.

Business focus prior to the merger

Prior to the completion of the merger and asset sale, ReShape Lifesciences described its business as centered on obesity and metabolic disease management. Its portfolio, as described in multiple news releases, included:

• Lap-Band® System and Lap-Band® 2.0 FLEX – FDA-approved, minimally invasive devices for long-term obesity treatment, positioned as alternatives to more invasive surgical stapling procedures.
• Obalon® balloon technology – A non-surgical, swallowable, gas-filled intragastric balloon designed to provide long-lasting weight loss.
• DBSN™ / vagal neuromodulation system – An investigational system based on vagus nerve block and stimulation technology for type 2 diabetes and metabolic disorders.
• Intragastric device patents – Intellectual property covering swallowable, degradable intragastric balloon systems with timed deflation and natural excretion features.

These disclosures position ReShape Lifesciences as a company focused on device-based interventions for obesity and metabolic disease, operating within the broader category of surgical and medical instrument manufacturing.

Corporate transformation into Vyome Holdings, Inc.

According to an August 19, 2025 Form 8-K, the merger between ReShape Lifesciences Inc. and Vyome Therapeutics, Inc. closed on August 15, 2025. At that time, the company changed its corporate name to Vyome Holdings, Inc., and Nasdaq approved continued listing of the combined company on The Nasdaq Capital Market. The trading symbol transitioned from RSLS to HIND as of the open of trading on August 15, 2025, as described in both SEC filings and Business Wire announcements.

Vyome Therapeutics, as described in multiple news releases, is a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, with a stated goal of building a healthcare platform spanning the US-India innovation corridor. Its immediate focus is leveraging clinical-stage assets to address immuno-inflammatory conditions. After the merger, Vyome’s business became the operating focus of the public entity now known as Vyome Holdings, Inc.

Status of RSLS as a historical ticker

Because the public company formerly known as ReShape Lifesciences Inc. has been renamed Vyome Holdings, Inc. and now trades under the symbol HIND, RSLS functions as a historical reference for the pre-merger entity. SEC filings explicitly state that Vyome Holdings, Inc. is the new name of the registrant, and that trading continues under the new symbol. There is no indication in the provided filings that RSLS remains an active trading symbol following the effective date of the merger and name change.

Key considerations for investors researching RSLS

Users examining RSLS-related information are often interested in:

• The historical business model and product portfolio of ReShape Lifesciences in weight loss and metabolic health devices.
• The terms and structure of the merger with Vyome Therapeutics, including share exchange mechanics and governance changes, as outlined in Form 8-K filings.
• The asset sale to Biorad Medisys and the transfer of ReShape’s device assets and related liabilities.
• The reverse stock split and its role in maintaining Nasdaq listing standards in connection with the merger.
• The transition of the public company into Vyome Holdings, Inc., with a new strategic focus on immuno-inflammatory and rare disease assets.

Frequently asked questions about RSLS